Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Broncus Holding Corp. ( (HK:2216) ) has provided an announcement.
Broncus Holding Corporation has announced that its BroncAblate® Lung Radiofrequency Ablation Generator has been approved for marketing in China by the National Medical Products Administration. This approval marks a significant step for the company as it begins the commercialization of the world’s first natural orifice transluminal radiofrequency ablation system for lung cancer. The system, which combines the BroncAblate® Generator and Catheter, offers a less invasive treatment option for lung tumors, potentially improving patient outcomes with fewer complications. This development positions Broncus Holding Corporation as a pioneer in the field of interventional lung cancer therapies, filling a global gap with its innovative approach.
More about Broncus Holding Corp.
Broncus Holding Corporation operates in the medical technology industry, focusing on innovative interventional devices for lung cancer treatment. The company’s primary product is the BroncAblate® Lung Radiofrequency Ablation System, which includes a generator and catheter designed for minimally invasive lung cancer treatment.
Average Trading Volume: 6,751,606
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.09B
See more data about 2216 stock on TipRanks’ Stock Analysis page.